Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00628394 · ClinicalTrials.gov registry record · Phase 4
Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
A Phase 4 study of Cognition in Schizophrenia, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 119
- Enrollment target
- 1
- Study location
NCT00628394 is a Phase 4 study of Cognition in Schizophrenia that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 119 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00628394, a Phase 4 study of Cognition in Schizophrenia, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 119 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving. During this study, we will test if cognitive remediation (computer games made to improve thinking), used along with a drug called atomoxetine, may help the problems in thinking as well as some of the symptoms of schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atomoxetine
Study Locations (1)
Texas
- The University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2003-09 |
| Est. Completion | 2011-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00628394
The ClinicalTrials.gov registry entry for NCT00628394 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cognition in Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00628394 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00628394 about?
NCT00628394 is a clinical study titled "Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation". This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving. During this study, we will test if cognitive remediation (computer games made to improve thinking), used along with a drug called at...
What is the current status of trial NCT00628394?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 119 participants. The study started on 2003-09. Estimated completion is 2011-02.
What conditions does trial NCT00628394 study?
This clinical trial studies the following conditions: Cognition in Schizophrenia.
What interventions are being tested in trial NCT00628394?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00628394?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00628394 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognition in Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.